References
Kralovics R. Genetic complexity of myeloproliferative neoplasms. Leukemia. 2008;22:1841–4.
Pikman Y, Lee BH, Mercher T, et al. MPLW515L is a novel somatic activating mutation in myelofibrosis with myeloid metaplasia. PLOS Med. 2006;3:e270.
Pardanani AD, Levine RL, Lasho T, et al. MPL515 mutations in myeloproliferative and other myeloid disorders: a study of 1182 patients. Blood. 2006;108:3472–6.
Beer PA, Campbell PJ, Scott LM, et al. MPL mutations in myeloproliferative disorders: analysis of the PT-1 cohort. Blood. 2008;112:141–9.
Chaligne R, Tonetti C, Besancenot R, Roy L, Marty C, Mossuz P, et al. New mutations of MPL in primitive myelofibrosis: only the MPL W515 mutations promote a G1/S-phase transition. Leukemia. 2008;22(8):1557–66.
Staerk J, Lacout C, Sato T, Smith SO, Vainchenker W, Constantinescu SN. An amphipathic motif at the transmembrane–cytoplasmic junction prevents autonomous activation of the thrombopoietin receptor. Blood. 2006;107:1864–71.
Ding J, Komatsu H, Wakita A, Kato-Uranishi M, Ito M, Satoh A, et al. Familial essential thrombocythemia associated with a dominant-positive activating mutation of the c-MPL gene, which encodes for the receptor for thrombopoietin. Blood. 2004;103:4198–200.
Acknowledgments
This work was supported in part by the Research Committee for Idiopathic Hematopoietic Disorders of the Japanese Ministry of Health, Labour and Welfare and the National Hospital Organization Research Fund.
Author information
Authors and Affiliations
Corresponding author
About this article
Cite this article
Ohashi, H., Arita, K., Fukami, S. et al. Two rare MPL gene mutations in patients with essential thrombocythemia. Int J Hematol 90, 431–432 (2009). https://doi.org/10.1007/s12185-009-0413-3
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s12185-009-0413-3